USPTO’s ruling favors $LPCN

Lipocine’s (LPCN) shares are up by 2% in early trading on increased volume after it announced a favorable ruling by the USPTO's Patent Trial and Appeal Board (PTAB) regarding its dispute with Clarus Therapeutics.  

Read more such news in our Daily Pharma Scoop at SeekingAlpha Marketplace.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *